(Q29615030)
Statements
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (English)
Shah NP
Nicoll JM
Nagar B
Gorre ME
Paquette RL
Kuriyan J
Sawyers CL
August 2002
117-25